149 related articles for article (PubMed ID: 3717931)
1. Randomized prospective study comparing moxalactam and cefoxitin with or without tobramycin for the treatment of serious surgical infections.
Tally FP; Kellum JM; Ho JL; O'Donnell TF; Barza M; Gorbach SL
Antimicrob Agents Chemother; 1986 Feb; 29(2):244-9. PubMed ID: 3717931
[TBL] [Abstract][Full Text] [Related]
2. Moxalactam vs tobramycin-clindamycin. A randomized trial in secondary peritonitis.
Stellato TA; Danziger LH; Hau T; Gauderer MW; Ferron JL; Gordon N
Arch Surg; 1988 Jun; 123(6):714-7. PubMed ID: 3285809
[TBL] [Abstract][Full Text] [Related]
3. Moxalactam versus clindamycin plus tobramycin in the treatment of obstetric and gynecologic infections.
Sweet RL; Ohm-Smith M; Landers DV; Robbie MO
Am J Obstet Gynecol; 1985 Aug; 152(7 Pt 1):808-17. PubMed ID: 3895947
[TBL] [Abstract][Full Text] [Related]
4. A randomized controlled trial of moxalactam versus clindamycin/tobramycin in the treatment of mixed anaerobic/aerobic infections.
Joshi M; Fitzpatrick BJ; Warren JW; Caplan ES; Tenney JH
Am Surg; 1986 Sep; 52(9):467-71. PubMed ID: 3530075
[TBL] [Abstract][Full Text] [Related]
5. Cefoxitin plus tobramycin and clindamycin plus tobramycin. A prospective randomized comparison in the therapy of mixed aerobic/anaerobic infections.
Nicolle LE; Harding GK; Louie TJ; Thomson MJ; Blanchard RJ
Arch Surg; 1986 Aug; 121(8):891-6. PubMed ID: 3524511
[TBL] [Abstract][Full Text] [Related]
6. Cephalosporin therapy in intraabdominal infections. A multicenter randomized, comparative study of cefotetan, moxalactam, and cefoxitin.
Wilson SE; Boswick JA; Duma RJ; Echols RM; Jemsek JG; Lerner R; Lewis RT; Najem AZ; Press RA; Rittenbury MS
Am J Surg; 1988 May; 155(5A):61-6. PubMed ID: 3287971
[TBL] [Abstract][Full Text] [Related]
7. Treatment of neutropenic infection: a randomized trial comparing latamoxef (moxalactam) with cephradine plus tobramycin.
Bezwoda WR; Derman DP; Perkins S; Cassel R
J Antimicrob Chemother; 1985 Feb; 15(2):239-45. PubMed ID: 3884566
[TBL] [Abstract][Full Text] [Related]
8. Moxalactam versus clindamycin plus tobramycin for the treatment of puerperal infections.
Pastorek JG; Faro S; Aldridge KE; Nicaud SK
South Med J; 1987 Sep; 80(9):1116-9. PubMed ID: 3306943
[TBL] [Abstract][Full Text] [Related]
9. Multicenter clinical trials comparing cefotetan with moxalactam or cefoxitin as therapy for obstetric and gynecologic infections.
Sweet RL; Gall SA; Gibbs RS; Hemsell DL; Knuppel RA; Lane TW; Miller RD; Newton ER; Poindexter AN; Reguero W
Am J Surg; 1988 May; 155(5A):56-60. PubMed ID: 3287970
[TBL] [Abstract][Full Text] [Related]
10. Cephalosporin therapy in intraabdominal infection: comparative studies of cefotetan, latamoxef and cefoxitin.
Wilson SE
J Chemother; 1989 Jul; 1(4 Suppl):820-2. PubMed ID: 16312655
[No Abstract] [Full Text] [Related]
11. A comparative study of netilmicin-cefoxitin and gentamicin-cefoxitin in surgical patients with serious systemic infection.
Bubrick MP; Howard RJ; Pancorbo S; Lorber RR; Chin TW; Yost R
Clin Ther; 1983; 5(5):515-24. PubMed ID: 6352035
[TBL] [Abstract][Full Text] [Related]
12. Prospective, randomized, comparative trials in the therapy for intraabdominal and female genital tract infections.
Harding GK; Nicolle LE; Haase DA; Aoki FY; Stiver HG; Blanchard RJ; Kirkpatrick JR
Rev Infect Dis; 1984; 6 Suppl 1():S283-92. PubMed ID: 6326244
[TBL] [Abstract][Full Text] [Related]
13. Comparison of single-dose moxalactam and a three-dose regimen of cefoxitin for prophylaxis in vaginal hysterectomy.
Rapp RP; Connors JE; Hager WD; Donaldson ES; van Nagell JR
Clin Pharm; 1986 Dec; 5(12):988-93. PubMed ID: 3542346
[TBL] [Abstract][Full Text] [Related]
14. Comparison of moxalactam with the combination of clindamycin and an aminoglycoside in the treatment of common surgical infections.
Rambo WM; Del Bene VE; Burkey LG; Collins CD; Richmond DK
Rev Infect Dis; 1982; 4 Suppl():S683-7. PubMed ID: 6218583
[TBL] [Abstract][Full Text] [Related]
15. Variations in susceptibility to latamoxef(moxalactam) and cefoxitin within the Bacteroides fragilis group.
Eley A; Greenwood D
J Antimicrob Chemother; 1984 Mar; 13(3):245-55. PubMed ID: 6725175
[TBL] [Abstract][Full Text] [Related]
16. Current status of therapy with cefoxitin.
McCloskey RV; Goren RC
Clin Ther; 1980; 3(2):66-79. PubMed ID: 7448845
[TBL] [Abstract][Full Text] [Related]
17. Treatment of intra-abdominal infections is appropriate with single-agent or combination antibiotic therapy.
Malangoni MA; Condon RE; Spiegel CA
Surgery; 1985 Oct; 98(4):648-55. PubMed ID: 3901372
[TBL] [Abstract][Full Text] [Related]
18. Antibiotic penetration in liver infection: a case of tobramycin failure responsive to moxalactam.
Schentag JJ; Heller AS; Hardy BG; Wels PB
Am J Gastroenterol; 1983 Oct; 78(10):641-4. PubMed ID: 6624739
[TBL] [Abstract][Full Text] [Related]
19. N-formimidoyl thienamycin: in vitro comparison with cefoxitin and tobramycin against clinical, bacterial isolates.
Digranes A; Dibb WL; Benonisen E
Acta Pathol Microbiol Immunol Scand B; 1983 Apr; 91(2):141-4. PubMed ID: 6603093
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of moxalactam in an animal model of subcutaneous abscesses: penetration into infected sites and in vivo activity against Bacteroides fragilis.
Bartlett JG; Joiner KA; Dezfulian M; Marien GJ
Rev Infect Dis; 1982; 4 Suppl():S664-9. PubMed ID: 6218580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
